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This study was designed to identify functionally im-
portant factor IX (FIX) residues. Using recombinant
techniques and cell culture, we produced a mutant FIX
with arginine at 338 changed to alanine (R338A-FIX).
This molecule had approximately 3 times greater clot-
ting activity than that of wild type FIX (wt-FIX) in the
activated partial thromboplastin assay. R338A-FIX re-
acted normally with a panel of three FIX specific mono-
clonal antibodies and migrated on sodium dodecyl sul-
fate-polyacrylamide gels indistinguishably from wt-FIX.
Using functional assays, we determined that R338A-
FIXa’s Kd for factor VIIIa (FVIIIa) was similar to that of
wt-FIXa. Our kinetic analysis, using factor X as sub-
strate, indicated that the mutation’s major effects were
a 3-fold increase in kcat and a 2-fold decrease in Km both
manifested only in the presence of FVIIIa. R338A-FIXa’s
increased catalytic efficiency did not result from abla-
tion of a thrombin sensitive site, reported to occur at
arginine 338, since in our assays the thrombin inhibitor,
hirudin, had no effect on activity of either wt-FIXa or
R338A-FIXa. R338A-FIXa and wt-FIXa had equal activ-
ity, with or without FVIIIa, toward the synthetic sub-
strate, methylsulfonyl-D-cyclohexylglycyl-arginine-p-ni-
troanilide. Interestingly, R338A-FIXa had reduced
affinity for heparin. Therefore, we propose that R338A-
FIXa’s increased activity is not due to an allosteric effect
on the active site, but that the Arg-338 residue is part of
an exosite that binds both factor X and the mucopolysac-
charide, heparin.
Factor IX (FIX),1 which plays a key role in both the intrinsic
and extrinsic coagulation pathway (1, 2), circulates as a 415-
amino acid, single-chain plasma zymogen (3). The zymogen of
FIX is activated by FXIa or by the tissue factor-FVIIa complex.
Specific cleavages between Arg-145 and Ala-146 and between
Arg-180 and Val-181 result in a light chain and heavy chain
linked by a single disulfide bond between cysteine 132 and
cysteine 289 (4). The structural organization of factor IX is
similar to that of the vitamin K-dependent blood clotting pro-
teins FVII, FX, and protein C (2). The approximately 45 amino
acids of the amino terminus comprise the g-carboxyglutamic
acid, or Gla, domain. This is followed by two epidermal growth
factor homology domains, an activation peptide and the cata-
lytic “heavy chain,” which is a member of the serine protease
family (3, 5, 6).
The major physiological function of factor IXa in the blood
coagulation cascade is to convert FX to FXa in a process that
requires the presence of phospholipid surface, calcium ions,
and FIXa’s protein cofactor, FVIIIa. FIXa alone is an extremely
poor protease, but when bound to FVIIIa to form the “intrinsic
FXase” complex it becomes a potent FX activator (7, 8). It has
been proposed that, upon binding FVIIIa, FIXa may undergo a
conformational change at or near the active site (9). The im-
portance of FIX is exemplified by the fact that patients with
defective FIX molecules suffer from hemophilia B, an X-linked,
recessive bleeding disorder that is clinically indistinguishable
from hemophilia A in patients who have no FVIII function.
Using recombinant techniques, we created mutant FIX mol-
ecules designed to locate the residues of FIXa that bind FVIIIa.
We have found one mutation, R338A-FIX, whose clotting ac-
tivity is 2.5–3 times that of wild type FIX. In an attempt to
understand the causes contributing to the increased clotting
activity of R338A-FIX, we have determined several functional
parameters. Our results demonstrate that the increased clot-
ting activity is FVIIIa-dependent and is due to an increased kcat




Oligonucleotides for in vitro mutagenesis were purchased from Life
Technologies, Inc. T7 DNA polymerase, T4 DNA ligase and restriction
enzymes were obtained from New England Biolabs (Beverly, MA). Se-
quenase 7-deaza-dGTP DNA sequencing kits were purchased from U. S.
Biochemical Corp. The anti-human FIX monoclonal antibodies used in
this study were A-1, A-5, and A-7, a gift from Dr. Kenneth J. Smith.
Purified normal human plasma FIX, FX, FXa, FXIa, and thrombin were
purchased from Enzyme Research Laboratories Inc. (South Bend, IN).
Coagulation control level 1, FIX-deficient plasma, FVIII-deficient
plasma, aPTT reagent, and standarded heparin were obtained from
Sigma. Purified normal human plasma FVIII was a gift from Roher
Biotechnology Inc. (Springfield, VA). Phosphatidylserine and phos-
phatidylcholine were purchased from Avanti Polar Lipids (Alabaster,
AL). Spectrozyme-FIXa (methylsulfonyl-D-cyclohexylglycyl-arginine-p-
nitroanilide) and Spectrozyme-FXa (methoxycarbonyl-D-cyclohexylgly-
cyl-glycyl-arginine-p-nitroanilide) were obtained from American Di-
agonostica Inc. (Greenwich, CT). Hirudin was obtained from Accurate
Chemical and Scientific Corp. (Westbury, NY). All other reagents were
of the highest purity available.
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Methods
In Vitro Mutagenesis and Construction of the Expression Plasmid—
Site-directed mutagenesis was performed as described by Kunkel (10).
The entire cDNA sequence was determined to ensure that the mutation
was correct and that no inadvertent mutations had been introduced.
Expression and Purification of Recombinant Proteins—Human em-
bryo kidney 293 cells were grown in a mixture of Dulbecco’s modified
Eagle’s medium and F-12 medium, supplemented with 10% fetal calf
serum. FIX and its mutants, in the vector pCMV5, a derivative of pCMV
mammalian expression vector (11), were cotransfected into cells with
pSV2 neo selection marker, using the calcium phosphate coprecipita-
tion method (12). G418-resistant cell clones were subcloned and ex-
panded. The supernatants from each clone were collected and assayed
for FIX expression using a radioimmunometric assay with FIX antibod-
ies. Stable clones with high expression levels of FIX were transferred
into 850-cm2 roller bottles for protein production in the serum-free
Dulbecco’s modified Eagle’s medium/F-12 medium supplemented with
100 units/ml penicillin and 100 mg/ml streptomycin, 5 mg/ml vitamin K,
and 10 mg/liter insulin-transferrin-sodium selenite. The supernatants
were collected every 24 h for 10 days and stored at 220 °C. For purifi-
cation, the frozen supernatants were thawed and EDTA and benzami-
dine-HCl were added (final concentration of 4 mM and 5 mM, respec-
tively). The supernatants were filtered through a 0.45 mM Millipore
filter to remove cell debris and incubated at 4 °C with overnight shak-
ing in Q Sepharose Fast Flow resin (2.5 ml of resin/liter of supernatant).
The resin was pre-equilibrated in 20 mM Tris-HCl, 15 mM NaCl, 2 mM
benzamidine-HCl, pH 7.4 (equilibration buffer). The resin was then
loaded in a column, washed with equilibration buffer containing 2 mM
EDTA for 4 h, and washed for another 1 h with equilibration buffer
without EDTA. FIX was eluted from the column with a 0–60 mM
calcium gradient, concentrated in a Centriprep-30, and stored at
280 °C.
Radioimmunometric Assay—Three monoclonal antibodies (A1, A5,
and A7) were used in the assay. A5 was employed at 10 mg/ml in 50 mM
NaHCO3 (pH 8.5) to coat a 96-well microtiter plate. Samples were
added to the antibody-coated wells. After incubation at 4 °C overnight,
the second antibody, A1 or A7, labeled with 125I by IODOBEADs ac-
cording to the manufacturer’s instructions (Pierce) was added at about
1 3 105 cpm/well. Unbound radioactive antibody was washed with
buffer (20 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, and 1 mM MgCl2,
pH 7.5) after a 4-h incubation, and the bound radioactive content of
each well was measured. The standard curve was obtained using
plasma FIX.
Analysis of Recombinant FIXs—SDS-PAGE was performed as de-
scribed by Laemmli (13). The total protein/well used on SDS-PAGE was
about 1 mg. Following electrophoresis, the purified proteins were visu-
alized by silver staining or Western blot analysis. The concentrations of
purified FIXs were determined spectrophotometrically assuming an
extinction coefficient e1% of 13.3, and the FIXa concentrations were
further determined by antithrombin III active site titration (14). Anal-
ysis of Gla content were kindly performed by Dr. Cindy Payne at Lilly
Research Laboratories.
Clotting Assay—One-stage activated partial thromboplastin time
(aPTT) assays were performed according to the manufacturer’s instruc-
tions (Sigma). For partial thromboplastin time (PTT) assays, the FIX
proteins were activated prior to the clotting test and phospholipids were
used instead of an activator. The ability of the sample to correct the
clotting time of FIX-deficient plasma was compared with a standard
curve utilizing purified plasma FIX in both assays. All experiments
were repeated on at least three times.
Activation of FIX by FXIa—wt-FIX or R338A-FIX was incubated
with FXIa at a molar ratio 100:1 in HEPES buffer (20 mM Hepes, 150
mM NaCl, pH 7.4) with 5 mM CaCl2 at 37 °C for 2 h or at a molar ratio
2000:1 in the same buffer at 37 °C for 4 h. The process of activation was
followed by removing aliquots at specific time points. The reaction was
stopped by adding SDS and 2-mercaptoethanol, after which the samples
were immediately boiled for 5 min and run on SDS-PAGE. Completely
activated samples, judged by SDS-PAGE and Western blot, were ali-
quoted and stored at 280 °C.
Activation of FVIII by Thrombin—FVIII (10–34 nM) was activated to
FVIIIa in HEPES buffer containing 20–64 nM thrombin for 5 min at
25 °C. The thrombin activity was then inhibited by further incubation
of FVIIIa-thrombin mixture with 100–300 nM hirudin, and 5 mM cal-
cium for an additional 5 min at 25 °C. The concentration of FVIII was
estimated from its activity in a one-stage aPTT assay, assuming the
concentration of FVIII in plasma to be 0.3 nM.
Kd Determination for the FIXazFVIIIa Interaction—Freshly prepared
0.4 nM FVIIIa (25 ml) containing 400 mM PSPC (15) (45% phosphatidyl-
serine, 55% phosphatidylcholine) was incubated with 25 ml of FIXa
varying from 0 to 20 nM for 5 min at 25 °C in HEPES buffer plus 5 mM
calcium, to form FXase. 200 nM FX and 1 mM Spectrozyme-FXa in 50 ml
were added, and the initial rate of FXa generation was determined on
the microplate reader.
FX Activation by FIXa in the Presence of Phospholipid—wt-FIXa or
mutant R338A-FIXa (50 ml, 50 nM) was incubated with 200 mM PSPC
vesicles, 10 mM calcium, and 0.5 mM Spectrozyme-FXa in a microplate
well for 5 min at 25 °C. Varying concentrations of FX (50 ml, between 0
and 400 nM) were added to this mixture, and the absorbance at 405 nm
was measured for 30 min on the microplate reader. The final concen-
trations were 25 nM FIXa, 100 mM PSPC, 0–200 nM FX, and 0.25 mM
Spectrozyme FXa.
FX Activation by FIXa in the Presence of Phospholipid and FVIIIa—
The assay was performed by incubation of 25 ml of freshly prepared
FVIIIa (0.4 or 1.6 nM) containing 400 mM PSPC with an equal volume of
FIXa (1 nM) for 5 min at 25 °C in HEPES buffer plus 1.0 mg/ml albumin,
10 mM calcium, and 0.5 mM Spectrozyme FXa to give a volume of 50 ml.
Reactions were initiated by the addition of 50 ml of varying concentra-
tions of FX. The rate of generation of FXa was determined on a micro-
plate reader. The final concentrations were 0.25 nM FIXa, 0.1 nM or 0.4
nM FVIIIa, 100 mM PSPC, 0–200 nM FX, and 0.25 mM Spectrozyme FXa.
The Effect of Hirudin on FIXazFVIIIa Binding—The experiments
were performed as described for the assay of FIX binding to FVIIIa,
except that in one group, 100 nM hirudin was added to completely
inhibit thrombin activity; in another group, no hirudin was added.
Electrophoretic Analysis of FXa’s Effect on FIXa—Purified plasma
wt-FIXa (2000 nM), FVIIIa (0.15 nM), FXa (300 nM), and calcium (5 mM)
were mixed and incubated at 25 °C. At different time points, samples
were removed, subjected to SDS-PAGE, and then silver-stained.
Hydrolysis of Synthetic Substrate Spectrozyme-FIXa—FIX was acti-
vated using FXIa at a molar ratio 2000:1 (FIX:FXIa) and the concen-
trations of activated proteins were confirmed using antithrombin III
active site titration (14). In the absence of FVIIIa, 50 ml of 100 nM
wt-FIXa or R338A-FIXa in HEPES buffer plus 33% ethylene glycol and
5 mM calcium was added to a 96-well microplate. Substrate cleavage
was initiated by the addition of another 50 ml of varying concentrations
of Spectrozyme-FIXa (0–8 mM) diluted in the same buffer, and the plate
was immediately assayed by monitoring the absorbance at 405 nm. The
final concentrations were 50 nM FIXa and 0–4 mM Spectrozyme-FIXa.
FIG. 1. SDS-PAGE analysis of R338A-FIX and wt-FIX. Purified
proteins from mutant R338A-FIX, recombinant wt-FIX, and plasma
FIX in a range of about 0.5–1 mg, were subjected to SDS-PAGE. Sam-
ples were run under reducing conditions as described in the Experimen-
tal Procedures section. The bands were visualized by silver staining.
Lane M shows the molecular weight marker (97, 66, 45, 31, 21, 14). 1.
R338A-FIX; 2. recombinant wt-FIX; 3. plasma FIX.
TABLE I
Antigenicity, g-carboxyglutamic acid, and clotting activity of the
mutant R338A and wild type factor IXs
Antigenicity is shown relative to plasma purified factor IX or pooled
normal plasma. The wells were coated with A5 mAb, and 125I-labeled
A1 mAb was used as a second antibody. Purified pooled plasma FIX was
used to construct a standard curve for both the aPTT and PTT assays.
ND, not determined.
Sample AntigenicityA5 and A1 Gla aPTT PTT
% % %
R338A-FIX 102 6 9 13 260 6 41 282 6 53
Recombinant wt-FIX 111 6 2 11.1 ND 110 6 16
Plasma purified wt-FIX 100 13.5 100 100
Pooled normal plasma 100 12a 94 6 18 ND
a The expected number of Gla (g-carboxyglutamic acid) residues per
FIX molecule is 12.
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In the presence of FVIIIa, 5 ml of 120 nM wt-FIXa or R338A-FIXa was
mixed with 35 ml of about 17 nM FVIIIa containing 142 mM PSPC. The
mixture was incubated at room temperature for 5 min to form FXase.
Then, 10 ml of varying concentration of substrate (0–20 mM Spec-
trozyme-FIXa) was added to start the reaction. The final concentrations
were 12 nM FIXa, 12 nM FVIIIa, 5 mM calcium, 100 mM PSPC, and 0–4
mM Spectrozyme-FIXa. The absorbance values at 405 nm were con-
verted into molar concentration of product, using an extinction coeffi-
cient of 9.65 3 103 M21 cm21. Data were fit (nonlinear least squares) to
the Michaelis-Menten equation using KaleidaGraph published by Syn-
ergy Software (PCS Inc.).
The Inhibition of wt-FIXa and R338A-FIXa by Heparin—wt-FIXa (8
nM, 25 ml) or R338A-FIXa was mixed with 25 ml of 1.6 nM FVIIIa in
HEPES buffer with 5 mM calcium and 200 mM PSPC and incubated at
25 °C for 5 min to form FXase. Varying concentrations (12–10,800 nM,
25 ml) of heparin (assuming that the molecular weight of standarded
heparin is about 15,000) in the same buffer plus 5 mM calcium was
added and incubated for another 5 min. The initial rate of FX activation
was determined by addition of 25 ml of a mixture containing of 800 nM
FX, 2 mM Spectrozyme-FXa, 5 mM calcium, and 1.0 mg/ml albumin.
Data Analysis: FIXa Activity—Absorbance of initial rate of FX acti-
vation mediated by FIXa was converted to nanomolar Xa/min by the
following equation (16, 17).
Absorbance 5 at2 1 bt 1 c (Eq. 1)
a gives the rate at which FXa cleaves the chromogenic substrate or the
rate at which FX is cleaved, b gives the amount of FXa present in the
zymogen FX, and c gives the amount of cleaved substrate at time 0.
FIXa Binding to FVIIIa—The Kd for FIXa binding to FVIIIa was
determined using Equation 2, where it is assumed that the rate of FXa
cleavage is directly proportional to the FIXazFVIIIa complex
concentration.
@FIXa z FVIIIa# 5
~@FIXa# t 1 @FVIIIa# t 1 Kd!
2
2
Î~@FIXa# t 1 @FVIIIa# t 1 Kd!2 2 4@FIXa# t @FVIIIa# t
2
(Eq. 2)
Inhibition of Intrinsic FXase by Heparin—The data from inhibition
experiments were fit to Equation 3, described as partial noncompetitive


















v is the initial velocity of FX activation. Vmax is the maximal velocity at
a saturating concentration of FX. Vmax(i) is the Vmax in the presence of
inhibitor. Ks is the dissociation constant for enzyme-substrate complex,
and the dissociate constant of enzyme-inhibitor complex is Ki. S is the
concentration of substrate, and I is the concentration of inhibitor. The
data were fit with KaleidaGraph.
RESULTS
The Expression and Purification of Mutant R338A-FIX or
Recombinant wt-FIX—The expression level of the carboxylated
FIX varied from 500 to 1000 ng/106 cells/24 h. SDS-PAGE
FIG. 2. Binding of R338A-FIXa and wt-FIXa to their cofactor,
FVIIIa. The effect of binding R338A-FIXa (open squares) and wt-FIXa
(closed squares) to FIX’s cofactor, FVIIIa, was assessed in the presence
of 100 mM PSPC vesicles at 5 mM CaCl2. FVIII (0.1 nM) was activated by
thrombin and after 5 min the thrombin was inhibited by 100 nM hiru-
din. Binding was measured by FIXazFVIIIa complex mediated FXa
generation as described in the Experimental Procedure section. Data
represent the mean 6 SD of 5 experiments. The Kd and Bmax values of
the R338A-FIXa were 0.75 6 0.10 nM, and 3.56 6 0.15 nM FXa/min,
respectively. For wt-FIXa, the Kd was 1.01 6 0.24 nM and Bmax was
1.30 6 0.10 nM FXa/min.
FIG. 3. Kinetics of FX activation by R338A-FIXa and wt-FIXa.
A, in the absence of FVIIIa. Twenty-five nM R338A-FIXa (open squares)
and wt-FIXa (closed squares) in 5 mM CaCl2 and 100 mM PSPC vesicles
were incubated with FX (0 to 200 nM). Data represent the mean 6 SD
of 2 experiments with duplicate wells. The Km and Vmax values for
R338A-FIXa were 53.50 6 7.44 nM, 2.58 6 0.13 nM FXa/min, respec-
tively. For wt-FIXa, the Km was 28.45 6 3.56 nM, and Vmax was 2.55 6
0.09 nM FXa/min. B, in the presence of 0.1 nM FVIIIa. 0.25 nM R338A-
FIXa (open squares) and wt-FIXa (closed squares) was used to activate
FX in the presence of 0.1 nM FVIIIa. Each concentration of FX is
represented by the mean 6 SD of 3 experiments. The Km for R338A-
FIXa was 7.72 6 0.65 nM, and Vmax was 2.47 6 0.04 nM FXa/min; For
wt-FIXa, the Km was 18.38 6 3.37 nM, and Vmax was 0.63 6 0.03 nM
FXa/min. (C). In the presence of 0.4 nM FVIIIa. FVIIIa (0.4 nM) was
incubated with 0.25 nM R338A-FIXa (open squares) or wt-FIXa (closed
squares), then used to activate FX. Each concentration of FX is the
mean 6 SD of 3 experiments. The Km and Vmax were 12.23 6 0.84 nM,
5.42 6 0.08 nM FXa/min for R338A-FIXa, and 19.64 6 1.79 nM, 2.46 6
0.06 nM FXa/min for wt-FIXa. All of the curves were determined from
fitting the data to the Michaelis-Menten equation.
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analysis demonstrated that both purified R338A-FIX and re-
combinant wt-FIX migrated as a single band with the same
molecular weight as plasma FIX (Fig. 1), and Gla analysis
showed full carboxylation of both mutant R338A-FIX and re-
combinant wt-FIX (Table I), further indicating the high purity
of the expressed proteins. In addition, both R338A-FIX and
recombinant wt-FIX bound to three FIX-specific monoclonal
antibodies with the same efficiency as did plasma-purified FIX
or pooled normal plasma (Table I).
Clotting Activity—The initial characterization of recombi-
nant FIX was a one-stage aPTT assay. Purified plasma FIX and
normal pooled plasma were employed as standards. The re-
sults, shown in Table I, indicate that R338A-FIX had 2.6-fold
higher clotting activity than normal FIX. To rule out the pos-
sibility that the increased clotting activity was due to trace
amounts of FIXa generated during protein purification, all the
FIX were activated and then assayed in FIX-deficient plasma
(PTT assay). As shown in Table I, the PTT clotting activity of
activated R338A-FIX was 2.8-fold higher than activated
plasma FIX. This result agrees well with results of the aPTT
assay and suggests that the increased activity is not the result
of activated FIXa contaminating the R338A-FIX preparation.
FIXa Binding to FVIIIa—We assumed that FXase activity is
directly proportional to the concentration of FIXazFVIIIa com-
plex (17). This is a reasonable assumption because, in the
conditions that we use, addition of FVIIIa to FIXa results in a
300–1000-fold increase in the FXase reaction rate. In the assay
of FIXa binding to FVIIIa, binding affinity was monitored
through a FXa generation mediated by FIXazFVIIIa complex.
The results of five experiments, each done in duplicate, are
shown in Fig. 2. When all the data were fit to Equation 2, the
apparent dissociation constant (Kd) for binding of R338A-FIXa
to FVIIIa was 0.75 6 0.10 nM compared with 1.01 6 0.24 nM for
plasma FIXa. This is consistent with the published binding
constants (17). The maximum rate of FX cleavage achieved,
however, was 2.7-fold greater for activated R338A-FIX than for
wt-FIXa (3.56 6 0.15 nM FXa/min and 1.30 6 0.10 nM/min,
respectively.)
FX Activation by FIXa in the Absence or Presence of Cofactor
FVIIIa—The kinetic parameters for cleavage of FX by R338A-
FIXa, plasma FIXa (data not shown), or recombinant wt-FIXa
were investigated in the absence or presence of their cofactor,
FVIIIa. In the absence of FVIIIa, the kcat values for R338A-
FIXa and wt-FIXa were 1.72 3 1023/s and 1.70 3 1023/s,
respectively, while the Km for R338A-FIXa was about 2 fold
higher compared with that of recombinant FIXa (Fig. 3A, Table
II). When FVIIIa at either 0.1 nM (Fig. 3B) or 0.4 nM (Fig. 3C)
was included in the reaction, the kcat of R338A-FIXa was 1.65
and 1.20/s, respectively, compared with 0.53 and 0.63/s for
recombinant wt-FIX (Table II). Moreover, in contrast to the
situation in the absence of FVIIIa, the Km of R338A-FIXa was
about 2-fold lower compared with wt-FIXa (Table II).
The Effect of Hirudin on the Mutant R338A-FIXa and wt-
FIXa Binding to Their Cofactor, FVIIIa—One obvious possibil-
ity for the increased activity of R338A-FIX is that replacing the
arginine by alanine eliminates a potential proteolytic cleavage
site. It has been reported, for example, that thrombin can
cleave FIX after residue 338 to render the FIX molecule inac-
tive (19, 20). This did not seem likely because the experiments
that demonstrated this phenomenon required a very large con-
centration of thrombin. Because hirudin is a potent inhibitor of
thrombin we repeated our binding experiments in the presence
and absence of hirudin. As shown in Fig. 4, hirudin had no
detectable effect on the maximum velocity achieved with re-
combinant wt-FIXa. Vmax was 1.27 6 0.12 nM FXa/min in the
absence of hirudin, and 1.35 6 0.15 nM FXa/min in its presence.
Thus, the cleavage of FIXa at Arg-338 by thrombin does not
explain the increased catalytic activity of R338A-FIXa.
Electrophoretic Analysis of FXa’s Effect on FIXa—Another
potential source of proteolysis in our experimental system is
the FXa generated during the reaction. To test the possibility
that FXa might cleave the heavy chain of FIXa at arginine 338,
we incubated purified plasma FIXa with FXa and FVIIIa. If
FXa can cleave FIXa at arginine 338, which is responsible for
the difference in activity between wt-FIXa and R338A-FIXa, it
would be easily observed by SDS-PAGE. As shown in Fig. 5, no
cleavage in the heavy chain of FIXa (Mr 28,000) was observed
when incubated for up to 120 min. Thus, reduced proteolysis of
FIG. 4. The effect of hirudin on R338A-FIXa and wt-FIXa bind-
ing to its cofactor FVIIIa. In parallel experiments, the effect of
hirudin on the binding of R338A-FIXa or wt-FIXa to FVIIIa was deter-
mined. The methods were as described in Fig. 2. In the presence (cross)
or absence (filled squares) of 100 nM hirudin, the Kd and Bmax of
wt-FIXa were similar; 0.85 6 0.29 nM and 1.35 6 0.15 nM FXa/min in
the presence of hirudin, and 0.38 6 0.15 nM, 1.27 6 0.12 nM FXa/min in
its absence. For R338A-FIXa, the Kd and Bmax in the presence of 100 nM
hirudin (filled circles) were 0.51 6 0.11 nM and 3.38 6 0.19 nM FXa/min
while in the absence of hirudin (open squares) the values were 0.40 6
0.06 nM, 3.39 6 0.12 nM FXa/min. Each point is the mean of 4 deter-
minations with the standard deviations shown.
TABLE II
The kinetic analysis of mutant R338A-FIXa and wt-FIXa
Km Vmax Enzyme kcat
a kcat/Km
nM nM FXa min21 nM s21 mol21 s21
Without FVIIIa
wt-FIXa 28.45 6 3.56 2.55 6 0.09 25 1.70 3 1023 5.98 3 104
R338A-FIXa 53.50 6 7.44 2.58 6 0.13 25 1.72 3 1023 3.22 3 104
With FVIIIa 0.1 nM
wt-FIXa 18.38 6 3.37 0.63 6 0.03 0.020 0.53 2.88 3 107
R338A-FIXa 7.72 6 0.65 2.47 6 0.04 0.025 1.65 2.14 3 108
With FVIIIa 0.4 nM
wt-FIXa 19.64 6 1.79 2.46 6 0.06 0.065 0.63 3.21 3 107
R338A-FIXa 12.23 6 0.84 5.42 6 0.08 0.075 1.20 9.81 3 107
a kcat 5 Vmax/[enzyme], in the presence of FVIIIa; the enzyme concentrations of FIXa z FVIIIa complex were calculated based on Equation 2 and
observed Kd values.
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R338A-FIXa by FXa compared with wt-FIXa does not explain
the increase in catalytic activity.
Hydrolysis of Synthetic Substrate by FIXa Alone or by the
FIXazFVIIIa Complex—Whether in the absence or presence of
FVIIIa, the Kcat of both R338A-FIXa and wt-FIXa for synthetic
peptidyl substrate, Spectrozyme-FIXa was similar (Table III).
Based on our experiments, the Kd of FIXa for FVIIIa is about 1
nM. Thus, the concentration of FIXazFVIIIa complex in these
experiments was ;9 nM (Equation 2), which was high enough
to measure any differences caused by changes in the active site
between R338A-FIXa and wt-FIXa. Although we used FIXa
concentration (12 nM) as an enzyme concentration in calculat-
ing kcat (Table III), there was no obvious difference in kcat if the
FIXazFVIIIa complex concentration (9 nM) was used. Interest-
ingly, we observed a small increase on Km for both enzymes in
the presence of FVIIIa.
The Inhibition of wt-FIXa and R338A-FIXa by Heparin—We
measured the effect of heparin on FXase at fixed concentrations
of FIXa, FVIIIa, FX, and phospholipids. The initial rate of FX
activation is indicated as a function of varying concentrations
of the inhibitor. The results shown in Fig. 6 represented means
from three different experiments and, as expected, revealed
that heparin inhibited FXa generation both by R338A-FXase
and wt-FXase. However, we observed a 2-fold difference in Ki
values (26 6 6.10 nM for R338A-FIXa and 12 6 1.66 nM for
wt-FIXa), and a 7-fold difference in Vmax(i) values (3.55 6 0.41
nM FXa/min for R338A-FIXa and 0.49 6 0.09 nM FXa/min for
wt-FIXa) for the two enzymes. At saturating concentrations of
heparin, the enzymes had residual activities of ;5% for wt-
FIXa and 17% for R338A-FIXa. This result is consistent with
heparin’s partial noncompetitive inhibition of FXase reported
previously (21).
DISCUSSION
Our original aim was to identify residues critical for the
interaction between FIXa and FVIIIa. Instead we found a mu-
tation, arginine 338 (C170) to alanine, that resulted in a FIX
molecule with 3 times more coagulant activity than recombi-
nant wild type or plasma FIX. In assays using various compo-
nents of the intrinsic FXase complex, the increased activity was
manifested only toward the macromolecular substrate FX and
only in the presence of FVIIIa. This increase is the result of a
3-fold increase in kcat and a 2-fold decrease in Km relative to
wild type.
There are several possible explanations for our observations.
First, changing arginine at 338 to alanine might increase the
affinity of FIXa for FVIIIa so that at a given concentration of
proteins, more FIXa would be complexed with FVIIIa, thus
increasing the effective enzyme concentration. A chimeric fac-
tor IXa with factor VII’s first epidermal growth factor-like
domain had increased activity for this reason (22). This could
account for the increase in kcat, but not the decrease in Km.
Inasmuch as we observe no significant difference for the Kd
between R338A-FIXa and FVIIIa relative to normal FIXa, this
model seems unlikely to fit our results.
Second, FVIIIa, through residue 338, may exert an allosteric
effect on the active site of FIXa. Complex formation between
FVIIIa and FIXa results in at least a 300-fold (Table II) and, in
some conditions, much greater (8) increase in kcat for FX acti-
vation. This has usually been interpreted in terms of a Michae-
lis complex formation preceded only by a bimolecular binding of
substrate to enzyme. The kcat is proportional to the difference
in free energy between the ground state (Michaelis complex)
and the transition state. Therefore, one possibility is that
FVIIIa binding alters the active site environment of FIXa and
changes the energy required to reach the transition state. Mu-
tation of R338A-FIXa could increase the kcat allosterically by
affecting this process. There is some evidence, not only for
factor IXa-factor VIIIa (9), but also for tissue factor-factor VIIa
(23) and thrombin-thrombomodulin (24), suggesting that cofac-
tor binding alters the enzyme’s active site configuration. On the
other hand, one previous report stated that FVIIIa had no
effect on FIXa’s small substrate cleavage (25). To test this, we
FIG. 5. SDS-PAGE analysis of FIXa cleavage by FXa. Purified
plasma wt-FIXa (2000 nM), FXa (300 nM) and FVIIIa (0.15 nM) were
incubated together at 25 °C for the indicated intervals. Aliquots were
removed at each time point and subjected to SDS-PAGE analysis. The
bands were visualized by silver staining. Lane 1. wt-FIXa control; lane
2. molecular weight marker (97, 66, 45, 31, 21, 14); lane 3–7, experi-
mental samples of FIXa taken at different time points.
FIG. 6. Inhibition of R338A-FIXa and wt-FIXa by heparin. Ei-
ther wt-FIXa (closed squares) or R338A-FIXa (open squares)(2 nM) was
incubated for 5 min at room temperature with 0.4 nM FVIIIa to form the
intrinsic FXase. The initial rates of FX activation were determined by
further incubation of above FXase with the varying concentrations of
heparin (from 3 nM to 2.7 mM), and then with a fixed concentration of FX
(200 nM) as described in the Experimental Procedures section. Data
represent the mean 6 SD of 3 experiments. The inhibition constants
(Ki) were 12.16 6 1.66 nM for wt-FIXa, 25.93 6 6.10 nM for R338A-FIXa
and the Vmax(i) values were 3.55 6 0.41 nM FXa/min for R338A-FIXa,
0.49 6 0.09 nM FXa/min for wt-FIXa when all of the data were fit to
Equation 3.
TABLE III
The kinetic analysis for hydrolysis of spectrozyme-FIXa by R338A-FIXa and wt-FIXa
Km Vmax/min Vmax/s Enzyme kcat
a
mM mM pNA mM pNA nM s21
wt-FIXa 1.62 7.26 0.12 50 2.40
R338A-FIXa 1.44 6.45 0.11 50 2.20
wt-FIXa 1 FVIIIa 2.50 1.53 0.026 12 2.17
R338A-FIXa 1 FVIIIa 3.50 1.62 0.027 12 2.25
a kcat 5 Vmax/[enzyme]. In the presence of FVIIIa, FIXa concentration is 12 nM and the FIXa z FVIIIa complex concentration is about 9 nM.
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employed the synthetic substrate Spectrozyme-FIXa to probe
the active site of R338A-FIXa. The results show that, for both
wt-FIXa and R338A-FIXa, the kcat values were approximately
the same (Table III) in the presence or absence of FVIIIa. This
indicates that the mutation itself does not alter the catalytic
event at the active pocket of FIXa. In addition, R338A-FIXa’s
factor VIIIa-dependent increase in catalytic activity is not in-
duced by an allosteric effect on the active site. This means that
FVIIIa binding to FIXa does not cause a rearrangement of
factor IXa’s catalytic residues, nor does it cause a change in the
rate of the catalytic event. Previous fluorescence studies with
active site modified FIXa indicate that binding FVIIIa may
cause a conformational change in the active site (9). Although
our results show no effect on kcat, we do observe a small Km
increase for both enzymes with FVIIIa. This result is consistent
with studies of FVa effect on FXa activity (26). Perhaps our
results and those of the fluorescence studies can be reconciled
by hypothesizing that, upon factor VIIIa binding, there is a
change in substrate binding site beyond the catalytic residues.
This causes the slight increase in Km that we observe with the
small substrate and the alteration in fluorescence intensity.
Therefore, our results both with the small substrate and
factor X are consistent with a model in which residue 338 is a
part of an extended macromolecular binding site (exosite). This
exosite may be made more accessible to FX when FIXa binds
FVIIIa, thus causing the observed changes in catalytic con-
stants. According to this model, when alanine replaces arginine
at residue 338, the smaller neutral side chain of alanine would
mitigate an unfavorable interaction during the initial binding
of FX to intrinsic tenase. This view is supported by our obser-
vations that R338A-FIXazFVIIIa’s Km for its substrate FX de-
creased 7-fold compared with R338A-FIXa alone (53.50 nM
versus 7.72 nM, Table II), whereas wt-FIXa’s Km decreased only
1.5-fold with FVIIIa. It is well known that FVIIIa accelerates
FX activation mainly by increasing kcat. Based on our results,
cofactor binding has little effect on small substrate catalysis.
Therefore, we think that cofactor binding affects the position-
ing of the substrate at the active site resulting in an increased
kcat in the presence of FVIIIa. This phenomenon is further
enhanced in R338A-FIXa. This same realignment of substrate
binding apparently has a different effect or no effect on the
small substrate. That is because when FVIIIa binds FIXa,
causing a rearrangement of the substrate binding site, part of
this site is involved only in macromolecular substrate binding.
This is where residue 338 is located.
Our results indicate that Arg-338 is not only part of a FX
binding site, but is also part of a heparin binding site. Heparin
is a partial noncompetitive inhibitor of the intrinsic FXase
complex (21). A partial noncompetitive inhibitor and substrate
can bind to the enzyme at the same time, and the enzyme-
substrate-inhibitor complex has some activity (18). Well char-
acterized exosites on thrombin are involved in a multiplicity of
functions, including cofactor, substrate, and heparin binding
(27–29). The a-helix 330–338 (C162–C170) of FIX is close to
part of the region designated exosite II in thrombin, which has
been implicated in heparin binding (30). The x-ray crystal
structure of porcine FIXa also suggests that this a-helix might
be a heparin binding site (6). Our results are consistent with
this prediction. The mutation of arginine to alanine not only
decreases the affinity for heparin by about 2-fold, but also
increases the Vmax(i) (Equation 3) by more than 7-fold. The
small Ki change may suggest that, as with thrombin, several
residues are necessary for heparin binding on FIX molecule
(29). Thus, we propose that Arg-338 is part of an exosite on
FIXa that interacts both with substrate and heparin. Whether
both functions are mediated by identical residues or only over-
lap remains to be shown.
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